[HTML][HTML] Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …
An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
such as the Omicron variants that are highly transmissible and immune evasive …
such as the Omicron variants that are highly transmissible and immune evasive …
An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved …
Z Liu, W Xu, Z Chen, W Fu, W Zhan, Y Gao… - Protein & …, 2022 - academic.oup.com
New threats posed by the emerging circulating variants of SARS-CoV-2 highlight the need to
find conserved neutralizing epitopes for therapeutic antibodies and efficient vaccine design …
find conserved neutralizing epitopes for therapeutic antibodies and efficient vaccine design …
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
L Wang, T Zhou, Y Zhang, ES Yang, CA Schramm… - Science, 2021 - science.org
INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2),
including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality …
including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality …
[HTML][HTML] A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
Z Yang, Y Wang, Y Jin, Y Zhu, Y Wu, C Li… - Signal transduction and …, 2021 - nature.com
The current COVID-19 pandemic has heavily burdened the global public health system and
may keep simmering for years. The frequent emergence of immune escape variants have …
may keep simmering for years. The frequent emergence of immune escape variants have …
[PDF][PDF] Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here,
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …
[PDF][PDF] Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …
[HTML][HTML] Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
S Halwe, A Kupke, K Vanshylla, F Liberta, H Gruell… - Viruses, 2021 - mdpi.com
Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …
[HTML][HTML] The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential …
CEZ Chan, SGK Seah, DH Chye, S Massey, M Torres… - PLoS …, 2021 - journals.plos.org
Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …
19, little is known about their mechanism (s) of action or effective dosing windows. We report …